ArticleDiscover oncology2025
Carvacrol-induced apoptosis via tumor suppressor gene activation and oxidative stress modulation in a rat model of breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carvacrol Selectively Induces Mitochondria-Related Apoptotic Signaling in Primary Breast Cancer-Associated Fibroblasts.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBreast cancer remains a significant global health challenge, despite advancements in chemotherapy. Targeted therapies utilizing plant-derived compounds are gaining attention, with Carvacrol-a monoterpene phenol-showing promise as an anticancer agent. This study evaluates Carvacrol antioxidant, anti-inflammatory, and pro-apoptotic effects in a DMBA-induced breast cancer rat model.
methodFemale rats were assigned to five groups: a normal/ healthy control (G1), a DMBA-induced cancer group monitored for 120 days (GII), and three tumor-bearing groups receiving Carvacrol (100 mg/kg b.w.) via oral (GIII), intraperitoneal (GIV), or combined routes (GV), administered thrice weekly for 12 weeks.
resultsCarvacrol treatment markedly counteracted the detrimental effects induced by DMBA. Intraperitoneal administration produced the strongest therapeutic response, significantly enhancing apoptotic markers (cytochrome c, TNF-α, FADD) while suppressing anti-apoptotic proteins (Bcl-2, DR2). Pro-apoptotic regulators (p53, p73, TRAIL) were up regulated, confirming activation of the intrinsic apoptotic pathway. Carvacrol also attenuated lipid peroxidation by reducing malondialdehyde (MDA) levels, while boosting total antioxidant capacity and improving inflammatory status. Moreover, restoration of liver and kidney function was observed through normalization of serum ALT, AST, urea, and creatinine levels, together with improved histopathological architecture. Although the intraperitoneal route achieved the greatest efficacy, all routes of administration produced significant improvements compared with the untreated DMBA group, highlighting both the therapeutic potential of Carvacrol and the importance of bioavailability. Overall, Carvacrol suppresses DMBA-induced breast cancer through activation of intrinsic and extrinsic apoptotic pathways, reduction of oxidative stress, and protection of vital organs, with the injection route demonstrating the highest effectiveness.
conclusionThe study supports Carvacrol potential as a complementary anticancer agent by enhancing apoptosis and reducing oxidative damage. Further research is required to optimize dosage and delivery for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.